Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Post by Hablandon Dec 18, 2021 5:37pm
421 Views
Post# 34243950

Hemostemix suing for damages

Hemostemix suing for damages I have read 98 of the 187 pages so far and my take is that Aspire and all their cohorts are screwed. They were blatantly fraudulent in their actions. They programmed the emails to automatically be forwarded to Aspire well after all contracts were terminated. This happened well into 2020 from what I can see and it took months before Hemostemix was aware of it and stopped it. Cooper had orchestrated this and they were still using Hemostemix email accounts to send to trial sites . Makofta was working from both sides and the directors didn't know. The later directors Friesen and Jenkins had no experience in the biotechnology sector and were loyal to Makofka and Woods. I cannot see how the defendant's in this case come away with anything. The thing is how long will this take to settle. 
<< Previous
Bullboard Posts
Next >>